Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Abbott Vascular |
---|---|
Information provided by: | Abbott Vascular |
ClinicalTrials.gov Identifier: | NCT00300131 |
• Prospective, open-labeled First in Man Clinical Investigation enrolling patients with visually estimated nominal vessel diameter of 3.0 mm and lesion length smaller 8 mm receiving a single 3.0 x 12 mm BVS Everolimus Eluting CSS containing 98 ug everolimus per cm² of surface area.
Condition | Intervention | Phase |
---|---|---|
Coronary Disease Coronary Artery Disease Coronary Restenosis |
Device: Bioabsorbable Everolimus Eluting Coronary Stent |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | Bioabsorbable Vascular Solutions (BVS) EECSS First in Man Clinical Investigation: A Clinical Evaluation of the BVS Everolimus Eluting CSS in the Treatment of Patients With Single de Novo Native Coronary Artery Lesions |
Enrollment: | 60 |
Study Start Date: | March 2006 |
Estimated Study Completion Date: | July 2011 |
Primary Completion Date: | July 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Bioabsorbable Vascular Solutions (BVS) Everolimus Eluting Coronary Stent System
|
Device: Bioabsorbable Everolimus Eluting Coronary Stent
Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease
|
Additionally, coronary vasomotion test may be done at 2 years post procedure
2 Patient Cohorts of 30 each. 6 months waiting period between recruitment of first and second cohort.
Pipeline products. Currently in development at Abbott Vascular. Not available for sale.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Target lesion must be located in a native epicardial vessel with visually estimated nominal vessel diameter of 3.0 mm
Exclusion Criteria:
Belgium | |
Onze-Lieve VrouweZiekenhuis | |
Aalst, Belgium | |
Denmark | |
Skejby Sygehus | |
Aarhus, Denmark | |
France | |
Centre Cardiologie du Nord | |
St. Denis, France, 93002 | |
Netherlands | |
Erasmus University Thorax Center | |
Rotterdam, Netherlands | |
New Zealand | |
Auckland City Hospital | |
Auckland, New Zealand | |
Poland | |
University Hospital | |
Krakow, Poland |
Principal Investigator: | John Ormiston, MD | Auckland City Hospital, New Zealand |
Responsible Party: | Abbott Vascular ( Abbott Vascular ) |
Study ID Numbers: | 05-370 |
Study First Received: | March 7, 2006 |
Last Updated: | June 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00300131 |
Health Authority: | New Zealand: Health and Disability Ethics Committees |
Bioabsorbable Coronary Stent Everolimus drug eluting stents stents angioplasty coronary artery disease |
total coronary occlusion coronary artery restenosis stent thrombosis vascular disease myocardial ischemia coronary artery stenosis |
Everolimus Arterial Occlusive Diseases Heart Diseases Myocardial Ischemia Vascular Diseases Constriction, Pathologic Ischemia |
Arteriosclerosis Coronary Restenosis Coronary Stenosis Thrombosis Coronary Disease Coronary Occlusion Coronary Artery Disease |
Immunologic Factors Physiological Effects of Drugs Cardiovascular Diseases Immunosuppressive Agents Pharmacologic Actions |